Recently we have reported a zosteriform murine infection model which employs the adoptive transfer of immune cells (All) to recipient infected mice to produce a disease that mimics human recurrent herpes simplex virus (HSV) disease. Mice were infected with HSV-1 by scarification at the lateroventral line of the neck; 2 days later, the mice received immune cells from HSV-1-infected syngeneic mice. Although virus was cleared more quickly from the target tissues of virus replication in recipient mice, ATI resulted in a heightened inflammatory response and delayed healing. This model was used to test the effects of topical formulations containing foscarnet and/or the antiinflammatory agent, hydrocortisone. Virus clearance and clinical signs, including ear thickness and zosteriform spread of lesions, were
Introduction
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), which cause orofacial and genital lesions, are common infections in man (Roizman & Sears, 1990) . The incidence of primary HSV-1 infections is greatest in children and serological evidence for infection may reach 80-90% in adults (Spruance, 1992) . Virus becomes latent in the neurons of the sensory ganglia and can be reactivated by variety of stimuli (Stevens & Cook, 1971; McLennan & Darby, 1980) . Recurrent cutaneous HSV infection occurs in a proportion of the adult population, causing inflammation, pain and discomfort. A recrudescence may last for up to 10-12 days, although virus shedding is usually restricted to the first few days. Several different specific inhibitors of HSV replication have been employed for topical therapy, including acyclovir (ACV) , foscarnet (PFA; phosphonoformate) and more recently, penciclovir (PCV). However, little beneficial effect on the disease (inflammation, swelling, redness, itching, discomfort and pain) has been reported for the therapy of recurrent labial or genital herpes studied. Treatment with 3% foscarnet accelerated virus clearance but had little effect on clinical parameters. By contrast, 0.5% hydrocortisone increased the titre and extended the presence of infectious virus for at least 6 days, although the reduction in clinical signs was greater than that obtained with topical foscarnet. Foscarnet in combination with hydrocortisone produced a marked reduction in clinical signswhile virus replication was reduced. These results are discussed in relation to the inflammation and discomfort experienced by patients and a possible role for anti-inflammatory formulations in the treatment of HSV reactivation episodes in man. Keywords: HSV; anti-inflammatory; foscarnet; antiviral; steroid; phosphonoformate.
except that lesions healed up to 1 day more quickly compared to control patients treated with placebo (Coreyet al., 1982; Spruance & Crumpacker, 1982; Shaw et al., 1985) .
Several animal models have provided valuable information on the pathogenesis of HSV (Hill et al., 1975; Stanberry et al., 1982; Harbour et al., 1983; Blyth et al., 1984) . The infections in these models, however, usually reflect primary disease in humans, both in the duration of virus shedding and effects of antiviral drugs. For example, in the guinea-pig back skin model, topical treatment with foscarnet was effective, although subsequent clinical trials on recurrent infection in man yielded disappointing results (Alenius et al., 1982) . Similarly, the guinea-pig model for HSV-2 exhibits recurrent lesions that occur spontaneously or were induced by means of UV-irradiation (Stanberry, 1989) . However, the number of animal developing lesions following stimulation is low and the duration of the lesions produced is shorter than observed in human recurrences (Stanberry, 1994) . Studies in both rabbit and murine models suggest that cell-mediated immune responses contribute significantly to the disease (Hendricks & Tumpey, 1990; Niemialtowski & Rouse, 1992) . Both direct tissue damage by the virus and the immune response to virus antigens are potential contributors to pathogenesis (Pepose, 1991) . The relevance of such information to human disease is likely to be dependent, at least in part, on how accurately the models mimic the disease in man. We have developed a mouse model for cutaneous herpesvirus infection in which a zosteriform spread oflesions occurs in the presence of adoptive transfer oflymphocytes. This model is designed to mimic recurrent disease seen in patients (ARAwan,] Harmenberg, 0 Flink and H] Field, unpublished results). The adoptive transfer model was used to study the effects of topical antiviral formulations and, in particular, to explore combinations of anti-inflammatory compounds and compounds with specific antiviral activity. Previously, corticosteroids in combination with antiviral agents have produced beneficial therapeutic responses in the treatment of recurrent herpetic stromal disease in the eye (0' Brien et al., 1996; Williams et al., 1977) and well-controlled clinical trials have documented this success (Power et al., 1992; Wilhelmus et al., 1994) . It has been assumed that the antiinflammatory properties of corticosteroids reduce the damage mediated by the host response to infection; however the precise role of the corticosteroids has not yet been identified, i.e. the limitation of tissue damage produced by the inflammatory responses stimulated by the growth of virus and infiltration of inflammatory cells into the tissue. The object of the present study was to use the adoptive transfer of immunity (ATI) model to study a series of topical preparations which contain the specific antiviral agent foscarnet, in combination with the antiinflammatory agent hydrocortisone, in order to predict beneficial combinations that may be of value in man.
Materials and Methods
Virus HSV-1 (strain SC16) was originally isolated from a clinical case of herpes labialis (Hill et al., 1975) . Virus was grown in BHK-21 (baby hamster kidney cells) and stored at -70°e. This strain has been widely used for the study of antiviral agents in murine infection models.
Inoculation of mice
Female BALB/c mice were obtained from Bantin and Kingman (Hull, UK). They were kept in quarantine for 1 week before use at 6-8 weeks old. The mice were provided with standard care. Three days before virus inoculation the 16-18 g mice were anaesthetized using isoflurane inhalation and were shaved on the right side of the neck with an electric trimmer. Inoculation was performed as described by Blyth et al. (1984) . Briefly, 15~ll of virus suspension 20 containing 2x10 5 p.fu. was placed on the skin in an area of 1 em" at the site to be scarified (right side of the ventral surface of the neck), approximately 4 mm above the ventral midline. Then 8-10 superficial light strokes were made by a hypodermic needle in a criss-cross pattern parallel to craniocaudal and ventro-dorsal axes to produce the scarification.
ATI
A group of immune donors were prepared by inoculation of 10 5 p.f.u. HSV-1 into the skin of both ears of anaesthetized female BALB/c mice. The donors were euthanized 7 days post-inoculation, the cervical draining lymph nodes removed and a suspension of lymph node cells was prepared in PBS. The cell suspensions were sieved through sterilized muslin cloth and cell viability was assessed by means of a trypan blue exclusion test. A suspension containing 2x10 7live immune cells in 80~L1 was transferred via the coccygeal vein to recipient mice that had been infected 2 days previously with HSV-1 by neck scarification. Control recipient mice received no cells.
Clinical signs. Groups of 10 mice were kept for clinical observation, and zoster score, ear thickness and body weight were measured daily. Mice were examined daily for clinical signs of the infection at both the primary and secondary sites ofvirus replication to day 12 post-infection and then again on days 15 and 19 post-infection Ear swelling. The thickness of the ear pinna, ipsilateral to the infection, was measured daily using an Engineers' micrometer. The uninfected ears were measured for companson.
Lesion severity (zoster score). The development of lesions on the neck (primary site) and pinna (zosteriform spread) was monitored visually using a magnifYing glass. Lesions were scored according to the following scale at the primary inoculation site: -4, no clinical signs; -3, one vesicle and swelling; -2, some vesicles; -1 local erosion; 0, ulceration of the local lesion. Positive scores were used to describe lesions at the secondary site of infection (ear pinna): 1, primary lesions plus isolated zosteriform lesion; 2, mild; 3, moderate; and 4, severe ulceration of confluent zosteriform lesions (Nagafuchi et al., 1979) . Thus the scores -4 to 0 describe the lesion development at the site of inoculation (primary lesion) whereas scores +1 to +4 describe the development of the zosteriform lesion (zoster score) at the secondary site. The swelling, erythema, scratching, apparent pain and behaviour of the animal at the time of measurements of zoster score and ear thickness were assessed subjectively and these data were also recorded. lation site was removed, placed in 1 ml Eagle's MElVI and stored whole at -70°e. To test for infectious virus, skin samples were homogenized in a glass homogenizer and titrated in BHK-21 cells as described by Field et at. (1995) . Virus plaques were stained and counted after 3 days incubation. With topical treatment at the infection site, there is a possibility that antiviral compounds may be present on the ear samples for virus isolation. The skin was therefore washed thoroughly before virus titration. The theoretical maximum concentration of foscarnet in the titration was not considered high enough to affect the plaque counts obtained.
Titration of infectious virus in the ear pinna

Application of topical creams
Mice were treated topically at 8 h intervals three times per day at 8 am, 4 pm and midnight with placebo cream or cream containing active ingredients. Approximately 25 mg of cream was applied to both surfaces of the ear flap on the ipsilateral ear and rubbed thoroughly with thumb and index finger. The topical treatment was started at day 4 post-infection and continued to day 7 post-infection inclusive. In order to avoid cross-contamination, placebo cream was applied first and gloves were changed between each experimental group. Topical preparations contained foscarnet cream (3% foscarnet in a cream base) or placebo cream (cream base without foscarnet), hydrocortisone (0.5%) (Hydrokortison; Kabi Pharmacia, Sweden) or a combination of 3% foscarnet with either 1% or 0.25% hydrocortisone (Astra Arcus, Sweden).
Statistical analysis for data evaluation
Statistical significance was evaluated using the Student's t-test (two-tailed for paired data).
Results
The effect of 3% foscarnet cream Topical therapy with 3% foscarnet from day 4 to 7 postinfection inclusive produced reduction in the ear thickness and zoster score but these values were not statistically significant [ Fig. 1a (i), b(i)]. Areas-under-the-curve (AUe) show that both ear thickness and zoster score were reduced by approximately 25% compared to the placebo control (Table 1) . However, foscarnet showed an antiviral effect and approximately 1 10glO reduction in virus titre was observed on day 7 post-infection [ Fig. 1c(i) ] and the AUe Antiviral Chemistry & Chemotherapy 9:1 was reduced to 44% of the control value (Table 1) . Virus was cleared earlier compared to the untreated control with no infectious virus detectable on day 9 post-infection.
The effect of 0.5% hydrocortisone The application of 0.5% hydrocortisone cream had a marked effect on clinical signs of disease in the ear pinna. The ears became less swollen and the reductions were highly significant on days 4 to 11 post-infection, inclusive [P<0.005; Fig. 1 a(ii) ]. Furthermore, the zoster score was also significantly reduced on days 7-9 post-infection [P<0.005; Fig. 1b (ii); Table 1 ). However, while the inflammatory changes were moderated by hydrocortisone, there was an opposite effect on virus replication such that the AUe was increased by greater than fourfold (Table 1) . This reflected increased virus titres at the time points tested and longer duration of infectious virus in the tissue [ Fig. 1c(ii) ].
Combinations containing foscarnet and hydrocortisone
Finally, a series of formulations were tested in which hydrocortisone was combined with foscarnet cream at two different concentrations. The combinations containing hydrocortisone had a beneficial effect on the clinical param eters of the disease: ear thickness and zoster score [Fig. 1a(iii, iv) ; 1b(iii, iv)]. However, virus replication in the skin was somewhat increased [ Fig. 1c (iii, iv); Table 1 ] but to a lesser extent than with hydrocortisone alone. The reduction in ear thickness obtained using the combination of 3% foscarnet with 0.25% hydrocortisone was highly significant from days 5 to 10 post-infection (P<0.005) and zoster score was also reduced, although this reduction was not significant. The reduction in ear swelling obtained using the combination of 3% foscarnet with 1% hydrocortisone was highly significant from days 4 to 12 post-infection (P<0.005); zoster score was also significantly reduced from day 7 to 12 post-infection (P<0.005). The AUe obtained with the combinations showed reductions of 45 to 68% for the clinical parameters coupled with an approximately twofold increase in infectious virus relative to the placebotreated controls (Table 1 ).
Discussion
Mter primary infection, complete recovery from labial or genital herpes is the rule, but virus establishes latency in the .................... . "'T"'-r-..--.---,r-..---r-.-,-- neurons of the sensory ganglia which can be reactivated by various stimuli (McLennan & Darby, 1980; Steiner & Kennedy, 1995) . Primary virus infection activates serological and cellular immune responses which help to clear virus from the infected mucocutaneous site. On reactivation, centrifugal spread of virus from the neurons of the ganglia gives rise to recrudescence at, or near to, the original site of infection (Stanberry, 1994; Spruance, 1992; Perna et al., 1987) . During recrudescence, relatively small numbers of virus particles may enter the epidermis via the axons where cytolytic virus replication and infiltration by inflammatory cells are associated with the irritation, burning and discomfort experienced by the patient. The period of virus shedding is generally much shorter than is the case during the primary episode. Clinical signs, including pain, swelling, redness and itching resulting from the inflammatory response to the virus appear to continue for several days after virus shedding can no longer be detected. Current specific antivirals that inhibit virus replication do not prevent the clinical course of recurrent infection when applied at the initiation of symptoms, where, although viral replication may be transient, the inflammatory response is still prolonged. We have developed a mouse model of zosteriform spread of HSV-1 in the presence of ATI which mimics human reactivation and we have used the model to study the effects of topical treatment with foscarnet alone or in combination with the anti-inflammatory agent, hydrocortisone.
Topical treatment with 3% foscarnet or 5% ACV cream (data not shown) applied to the ears of mice three times daily produced only moderate reductions in the clinical parameters of lesion score and ear thickness. These moderate effects on the clinical course of the disease are similar to those previously described in clinical trials of topical foscarnet for the treatment of recurrent cutaneous herpes in immuncompetent patients (Barton et al., 1986; Spruance et al., 1986) . Examination of the virus titres in the ears on day 7 post-infection showed, however, that antiviral treatments significantly reduced the virus titre compared to placebo. Thus, as in man, the benefit of treatment in terms of reduction of virus replication was not reflected in clinical benefit as determined quantitatively in the infection modeL
In contrast, treatment with the anti-inflammatory agent hydrocortisone had a beneficial effect on ear swelling and the zoster score, and pain (the latter suggested by the behaviour of animals during the treatment). However, hydrocortisone significantly increased virus replication both in intensity and duration, so that detectable virus could be isolated on day 15 post-infection, the last timepoint tested [ Fig. 1c(ii) ]. Presumably the chronic virus shedding was associated with more tissue damage as a direct result ofvirus replication in the site of infection. The combination of the specific antiviral compound, foscarnet with different concentrations of hydrocortisone had a Antiviral Chemistry & Chemotherapy 9:1 H5V-1 anti-inflammatory combinations beneficial effect on ear thickness and the zoster score while virus replication was reduced (although the reduction in virus titre was less than that obtained with foscarnet alone).
Although a systematic series of combinations containing the two components was not tested this study, it was generally observed that increasing the concentration of hydrocortisone and decreasing the concentration of foscarnet resulted in benefit measured by the clinical parameters, but this was balanced by the increase in, and prolongation of, virus replication. The study indicates that the mouse model can be used to optimize the relative concentrations of the active components of such combinations.
Our data suggest that reducing viral replication per se is insufficient to produce a significant reduction in clinical signs, which result from the inflammatory response triggered by the presence of the virus. This is consistent with the generally poorer effects of topical treatment with antiviral drugs and the length and severity of symptoms of recurrent herpesvirus infection in immunocompetent adults (Shaw et al., 1985; Sacks et al., 1987) . The combination of a topical antiviral agent with an anti-inflammatory agent is reported to produce beneficial effects in herpes keratitis (McGill, 1985; O'Brien et a, 1996; Wilhelmus et al., 1994) and antimicrobial agents in conjunction with topical steroids are widely used in other infections such as fungal skin diseases. The results from the present study help to clarify the mechanism behind the clinical symptomatology of recurrent cutaneous HSV infection and offer a promise for the development ofimproved topical treatment for recurrent genital or labial herpes in immunocompetent persons. We are currently investigating alternative (nonsteroidal) anti-inflammatory drugs in the same modeL
In conclusion, using an animal model which mimics recurrent herpes in immuncompetent individuals, we have shown that reducing viral replication by antiviral treatment alone is not necessarily sufficient to alter significantly the clinical signs of recurrent herpes. A combination of an antiviral agent with a substance capable ofreducing inflammation was more effective. However, it is recognized that there is a delicate balance between the beneficial effects of the inflammatory response in relation to the natural inhibition of virus multiplication and the damaging effects of the lytic virus manifested in necrosis and/or scar formation; caution is required before extrapolating these animal data to man. Such combinations, however, do offer promise for the topical treatment of recurrent herpes in immunocompetent individuals. Astra Arcus AB for providing us with the topical formulations.
